These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32417122)

  • 1. Reply to Cosimo De Nunzio, Giacomo Novara, Rocco Damiano, Riccardo Bartoletti, Andrea Tubaro, and Vincenzo Ficarra's Letter to the Editor re: Giorgio Ivan Russo, Carmen Scandura, Marina Di Mauro, et al. Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2020.01.002. New Evidence Changing Clinical Practice or Misunderstanding of Statistical Analyses? The Case of Serenoa repens and α-Blockers.
    Russo GI; Cacciamani G; Cocci A
    Eur Urol Focus; 2021 May; 7(3):662-663. PubMed ID: 32417122
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Giorgio Ivan Russo, Carmen Scandura, Marina Di Mauro, et al. Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2020.01.002: New Evidence Changing Clinical Practice or Misunderstanding of Statistical Analyses? The Case of Serenoa repens and α-Blockers.
    De Nunzio C; Novara G; Damiano R; Bartoletti R; Tubaro A; Ficarra V;
    Eur Urol Focus; 2021 Jul; 7(4):894-896. PubMed ID: 32418876
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials.
    Russo GI; Scandura C; Di Mauro M; Cacciamani G; Albersen M; Hatzichristodoulou G; Fode M; Capogrosso P; Cimino S; Marcelissen T; Cornu JN; Gacci M; Minervini A; Cocci A;
    Eur Urol Focus; 2021 Mar; 7(2):420-431. PubMed ID: 31952967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reply to Eleonora Rosato, Riccardo Lombardo, Vincenzo Li Marzi, Enrico Finazzi Agrò, Cosimo De Nunzio, and Simone Albisinni's Letter to the Editor re: Rano Matta, Refik Saskin, Sarah Neu, et al. Predicting Mirabegron Treatment Response in Patients with Overactive Bladder: A Post Hoc Analysis of Data from Clinical Trials. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.04.001.
    Matta R
    Eur Urol Focus; 2024 Jul; 10(4):671. PubMed ID: 37858406
    [No Abstract]   [Full Text] [Related]  

  • 5. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.
    MacDonald R; Tacklind JW; Rutks I; Wilt TJ
    BJU Int; 2012 Jun; 109(12):1756-61. PubMed ID: 22551330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Novara G; Giannarini G; Alcaraz A; Cózar-Olmo JM; Descazeaud A; Montorsi F; Ficarra V
    Eur Urol Focus; 2016 Dec; 2(5):553-561. PubMed ID: 28723522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter to the editorResponse to: Russo A, Capogrosso P, La Croce G, et al. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia. Expert Opin Drug Saf. 2016 Jun;1:1-10.
    Arena S
    Expert Opin Drug Saf; 2016 Oct; 15(10):1449. PubMed ID: 27558894
    [No Abstract]   [Full Text] [Related]  

  • 8.
    Trivisonno LF; Sgarbossa N; Alvez GA; Fieiras C; Escobar Liquitay CM; Jung JH; Franco JVA
    Investig Clin Urol; 2021 Sep; 62(5):520-534. PubMed ID: 34488251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serenoa repens for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Current Evidence and Its Clinical Implications in Naturopathic Medicine.
    Ooi SL; Pak SC
    J Altern Complement Med; 2017 Aug; 23(8):599-606. PubMed ID: 28436684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reply to Carmen Gravina, Riccardo Lombardo, and Cosimo De Nunzio's Letter to the Editor re: Yash S. Khandwala, Simon John Christoph Soerensen, Shravan Morisetty, et al. The Association of Tissue Change and Treatment Success During High-intensity Focused Ultrasound Focal Therapy for Prostate Cancer. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2022.10.010.
    Sonn G; Khandwala Y
    Eur Urol Focus; 2023 Sep; 9(5):822-823. PubMed ID: 37012086
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to Ivan Mauricio Plata, Julián Azuero, and Valentina García's Letter to the Editor re: Massimiliano Creta, Giorgio I. Russo, Naeem Bhojani, et al. Bladder Outlet Obstruction Relief and Symptom Improvement Following Medical and Surgical Therapies for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Systematic Review. Eur Urol. 2024;86:315-326.
    Creta M; Cornu JN; Fusco F
    Eur Urol; 2024 Nov; 86(5):e121-e122. PubMed ID: 39089919
    [No Abstract]   [Full Text] [Related]  

  • 12. Serenoa repens for benign prostatic hyperplasia.
    Wilt T; Ishani A; Mac Donald R
    Cochrane Database Syst Rev; 2002; (3):CD001423. PubMed ID: 12137626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phytotherapy for benign prostatic hyperplasia.
    Wilt TJ; Ishani A; Rutks I; MacDonald R
    Public Health Nutr; 2000 Dec; 3(4A):459-72. PubMed ID: 11276294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
    Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
    BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reply to Carmen Gravina, Riccardo Lombardo, and Cosimo De Nunzio's Letter to the Editor re: Georges Mjaess, Alexandre Peltier, Jean-Baptiste Roche, et al. A Novel Nomogram to Identify Candidates for Focal Therapy Among Patients with Localized Prostate Cancer Diagnosed via Magnetic Resonance Imaging-Targeted and Systematic Biopsies: A European Multicenter Study. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.04.008.
    Mjaess G; Roumeguère T; Diamand R
    Eur Urol Focus; 2024 Jan; 10(1):75-76. PubMed ID: 37543515
    [No Abstract]   [Full Text] [Related]  

  • 16. Observational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project.
    Bertaccini A; Giampaoli M; Cividini R; Gattoni GL; Sanseverino R; Realfonso T; Napodano G; Fandella A; Guidoni E; Prezioso D; Galasso R; Cicalese C; Scattoni V; Armenio A; Conti G; Corinti M; Spasciani R; Liguori G; Lampropoulou N; Martorana G
    Arch Ital Urol Androl; 2012 Sep; 84(3):117-22. PubMed ID: 23210402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
    Ye Z; Huang J; Zhou L; Chen S; Wang Z; Ma L; Wang D; Wang G; Wang S; Liang C; Qiu S; Gu X; Liu J; Weng Z; Wu C; Wei Q; Xie L; Wu W; Cheng Y; Hu J; Wang Z; Zeng X
    Urology; 2019 Jul; 129():172-179. PubMed ID: 30880074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Mauro Gacci, Giovanni Corona, Matteo Salvi, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003.
    Yuan JQ; Yang ZY; Mao C
    Eur Urol; 2012 Aug; 62(2):e35; author reply e36-8. PubMed ID: 22656724
    [No Abstract]   [Full Text] [Related]  

  • 19. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia.
    Russo A; Capogrosso P; La Croce G; Ventimiglia E; Boeri L; Briganti A; Damiano R; Montorsi F; Salonia A
    Expert Opin Drug Saf; 2016 Dec; 15(12):1661-1670. PubMed ID: 27232207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serenoa repens for benign prostatic hyperplasia.
    Wilt T; Ishani A; Stark G; MacDonald R; Mulrow C; Lau J
    Cochrane Database Syst Rev; 2000; (2):CD001423. PubMed ID: 10796790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.